Antibodies to peptidoglycan in patients with spondylarthritis: A clue to disease aetiology?

H. Park, H. R. Schumacher, A. R. Zeiger, James (Jim) Rosenbaum

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Although the aetiology of the spondylarthritic diseases, ankylosing spondylitis and Reiter's syndrome, is obscure, a clue to the pathogenesis might be an animal model, adjuvant arthritis. Rats with this disease develop a spectrum of pathology with marked similarity to the spondylarthritides. Since peptidoglycan, a major cell wall component of most bacteria is causally implicated in adjuvant arthritis, we sought evidence that peptidoglycan exposure accompanies both Reiter's syndrome and ankylosing spondylitis. Antibodies to the D-Ala-D-Ala moiety of peptidoglycan were measured by a sensitive and specific ELISA. Antibodies were elevated significantly in patients with ankylosing spondylitis or Reiter's syndrome, but not in patients with rheumatoid arthritis or degenerative joint disease in comparison with normal controls. The findings should be considered preliminary, since only a minority of patients had increased antibody titres. However, the findings are compatible with the hypothesis that peptidoglycan is causally related to spondylarthritis. Antibodies to other moieties in the peptidoglycan molecule might be a more sensitive test for significant exposure.

Original languageEnglish (US)
Pages (from-to)725-728
Number of pages4
JournalAnnals of the Rheumatic Diseases
Volume43
Issue number5
StatePublished - 1984

Fingerprint

Spondylarthritis
Peptidoglycan
Reactive Arthritis
Ankylosing Spondylitis
Antibodies
Experimental Arthritis
Pathology
Cellular Structures
Osteoarthritis
Cell Wall
Rats
Rheumatoid Arthritis
Bacteria
Animals
Animal Models
Enzyme-Linked Immunosorbent Assay
Cells
Molecules

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Antibodies to peptidoglycan in patients with spondylarthritis : A clue to disease aetiology? / Park, H.; Schumacher, H. R.; Zeiger, A. R.; Rosenbaum, James (Jim).

In: Annals of the Rheumatic Diseases, Vol. 43, No. 5, 1984, p. 725-728.

Research output: Contribution to journalArticle

@article{91c6a787eb584bb8853f65aa46e6c83f,
title = "Antibodies to peptidoglycan in patients with spondylarthritis: A clue to disease aetiology?",
abstract = "Although the aetiology of the spondylarthritic diseases, ankylosing spondylitis and Reiter's syndrome, is obscure, a clue to the pathogenesis might be an animal model, adjuvant arthritis. Rats with this disease develop a spectrum of pathology with marked similarity to the spondylarthritides. Since peptidoglycan, a major cell wall component of most bacteria is causally implicated in adjuvant arthritis, we sought evidence that peptidoglycan exposure accompanies both Reiter's syndrome and ankylosing spondylitis. Antibodies to the D-Ala-D-Ala moiety of peptidoglycan were measured by a sensitive and specific ELISA. Antibodies were elevated significantly in patients with ankylosing spondylitis or Reiter's syndrome, but not in patients with rheumatoid arthritis or degenerative joint disease in comparison with normal controls. The findings should be considered preliminary, since only a minority of patients had increased antibody titres. However, the findings are compatible with the hypothesis that peptidoglycan is causally related to spondylarthritis. Antibodies to other moieties in the peptidoglycan molecule might be a more sensitive test for significant exposure.",
author = "H. Park and Schumacher, {H. R.} and Zeiger, {A. R.} and Rosenbaum, {James (Jim)}",
year = "1984",
language = "English (US)",
volume = "43",
pages = "725--728",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "5",

}

TY - JOUR

T1 - Antibodies to peptidoglycan in patients with spondylarthritis

T2 - A clue to disease aetiology?

AU - Park, H.

AU - Schumacher, H. R.

AU - Zeiger, A. R.

AU - Rosenbaum, James (Jim)

PY - 1984

Y1 - 1984

N2 - Although the aetiology of the spondylarthritic diseases, ankylosing spondylitis and Reiter's syndrome, is obscure, a clue to the pathogenesis might be an animal model, adjuvant arthritis. Rats with this disease develop a spectrum of pathology with marked similarity to the spondylarthritides. Since peptidoglycan, a major cell wall component of most bacteria is causally implicated in adjuvant arthritis, we sought evidence that peptidoglycan exposure accompanies both Reiter's syndrome and ankylosing spondylitis. Antibodies to the D-Ala-D-Ala moiety of peptidoglycan were measured by a sensitive and specific ELISA. Antibodies were elevated significantly in patients with ankylosing spondylitis or Reiter's syndrome, but not in patients with rheumatoid arthritis or degenerative joint disease in comparison with normal controls. The findings should be considered preliminary, since only a minority of patients had increased antibody titres. However, the findings are compatible with the hypothesis that peptidoglycan is causally related to spondylarthritis. Antibodies to other moieties in the peptidoglycan molecule might be a more sensitive test for significant exposure.

AB - Although the aetiology of the spondylarthritic diseases, ankylosing spondylitis and Reiter's syndrome, is obscure, a clue to the pathogenesis might be an animal model, adjuvant arthritis. Rats with this disease develop a spectrum of pathology with marked similarity to the spondylarthritides. Since peptidoglycan, a major cell wall component of most bacteria is causally implicated in adjuvant arthritis, we sought evidence that peptidoglycan exposure accompanies both Reiter's syndrome and ankylosing spondylitis. Antibodies to the D-Ala-D-Ala moiety of peptidoglycan were measured by a sensitive and specific ELISA. Antibodies were elevated significantly in patients with ankylosing spondylitis or Reiter's syndrome, but not in patients with rheumatoid arthritis or degenerative joint disease in comparison with normal controls. The findings should be considered preliminary, since only a minority of patients had increased antibody titres. However, the findings are compatible with the hypothesis that peptidoglycan is causally related to spondylarthritis. Antibodies to other moieties in the peptidoglycan molecule might be a more sensitive test for significant exposure.

UR - http://www.scopus.com/inward/record.url?scp=0021189471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021189471&partnerID=8YFLogxK

M3 - Article

C2 - 6497464

AN - SCOPUS:0021189471

VL - 43

SP - 725

EP - 728

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 5

ER -